Sodium nitrite attenuates hypertension-in-pregnancy and blunts increases in soluble fms-like tyrosine kinase-1 and in vascular endothelial growth factor

Nitric Oxide. 2016 Jul 1:57:71-78. doi: 10.1016/j.niox.2016.05.004. Epub 2016 May 12.

Abstract

Preeclampsia is a pregnancy-associated disorder characterized by hypertension with uncertain pathogenesis. Increases in antiangiogenic soluble fms-like tyrosine kinase-1 (sFlt-1) and reductions in nitric oxide (NO) bioavailability have been observed in preeclamptic women. However, the specific mechanisms linking these detrimental changes to the hypertension-in-pregnancy are not clearly understood. In this regard, while recent findings have suggested that nitrite-derived NO formation exerts antihypertensive and antioxidant effects, no previous study has examined these responses to orally administered nitrite in hypertension-in-pregnancy. We then hypothesized restoring NO bioavailability with sodium nitrite in pregnant rats upon NO synthesis inhibition with N(omega)-nitro-l-arginine methyl ester (L-NAME) attenuates hypertension and high circulating levels of sFlt-1. Number and weight of pups and placentae were recorded to assess maternal-fetal interface. Plasma sFlt-1, vascular endothelial growth factor (VEGF) and biochemical determinants of NO formation and of antioxidant function were measured. We found that sodium nitrite blunts the hypertension-in-pregnancy and restores the NO bioavailability, and concomitantly prevents the L-NAME-induced high circulating sFlt-1 and VEGF levels. Also, our results suggest that nitrite-derived NO protected against reductions in litter size and placental weight caused by L-NAME, improving number of viable and resorbed fetuses and antioxidant function. Therefore, the present findings are consistent with the hypothesis that nitrite-derived NO may possibly be the driving force behind the maternal and fetal beneficial effects observed with sodium nitrite during hypertension-in-pregnancy. Certainly further investigations are required in preeclampsia, since counteracting the damages to the mother and fetal sides resulting from hypertension and elevated sFlt-1 levels may provide a great benefit in this gestational hypertensive disease.

Keywords: Hypertension-in-pregnancy; N(G)-nitro-l-arginine methyl ester; Rats; Sodium nitrite.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / administration & dosage
  • Antioxidants / therapeutic use*
  • Blood Pressure / drug effects
  • Female
  • Hypertension, Pregnancy-Induced / chemically induced
  • Hypertension, Pregnancy-Induced / metabolism
  • Hypertension, Pregnancy-Induced / physiopathology
  • Hypertension, Pregnancy-Induced / prevention & control*
  • Litter Size / drug effects
  • Male
  • NG-Nitroarginine Methyl Ester
  • Nitrates / blood
  • Nitric Oxide / antagonists & inhibitors
  • Nitric Oxide / blood
  • Nitrites / blood
  • Organ Size
  • Placenta / drug effects
  • Placenta / physiopathology
  • Pregnancy
  • Rats, Wistar
  • Sodium Nitrite / administration & dosage
  • Sodium Nitrite / therapeutic use*
  • Vascular Endothelial Growth Factor A / metabolism*
  • Vascular Endothelial Growth Factor Receptor-1 / metabolism*

Substances

  • Antioxidants
  • Nitrates
  • Nitrites
  • Vascular Endothelial Growth Factor A
  • vascular endothelial growth factor A, rat
  • Nitric Oxide
  • Flt1 protein, rat
  • Vascular Endothelial Growth Factor Receptor-1
  • Sodium Nitrite
  • NG-Nitroarginine Methyl Ester